# Scribe Therapeutics

> CRISPR-based genetic medicine platform spun out of Jennifer Doudna's lab.

## Why it is interesting

Industrialized CRISPR enzyme engineering for in vivo therapies — a16z-led Series A before Biogen partnership headlines.

## Profile

- **Stage:** growth
- **Status:** private
- **Industries:** healthtech, biotech-life-sciences
- **Coverage:** full
- **Last updated:** 2026-07-24

## Key facts

- Series A (Oct 2020): $20M led by a16z (a16z announcement, Businesswire)
- Biogen collaboration on neurodegeneration programs (company press)
- Co-investors: no additional institutional investors disclosed in public sources reviewed 2026-07-24

## Investors in our directory

- https://venturecapitaltracker.com/fund/andreessen-horowitz

## Related articles

- https://venturecapitaltracker.com/2026-a16z-hot-portfolio-companies

---
Source: https://venturecapitaltracker.com/startup/scribe-therapeutics